You are now leaving the pages of www.gilead.com intended for U.S. audiences. The information in this section is intended for visitors outside the United States.
Gilead Sciences Acquires Rights To Novel Oncology Compound From Southern Research Institute
Gilead Sciences Announces Private Offering of Convertible Subordinated Notes
Tamiflu™ Granted FDA Approval for Treatment of Flu in Children
Roche's Oral Flu Drug Tamiflu™ Gets Approval in Japan
Gilead Sciences Receives Approval to Initiate Clinical Trials in China for Adefovir Dipivoxil, an Investigational Compound for the Treatment of Chronic Hepatitis B Infection
Gilead Sciences Initiates Private Placement of Convertible Subordinated Notes
Gilead Sciences Announces License Agreement for Investigational Cancer Compound with Glaxo Wellcome PLC
Roche's Tamiflu™ Granted FDA Approval for the Prevention of Influenza
Study Results Published in Journal of Clinical Infectious Diseases Demonstrate That Ambisome® Has an Improved Safety Profile Compared to Abelcet®
Gilead Sciences Board of Directors Approves Proposed Increase in Authorized Capital for Planned 2-for-1 Stock Split
Gilead Begins Phase II Study of NX 211, Investigational Compound for the Treatment of Patients with Topotecan Resistant Ovarian Cancer
Gilead Sciences Announces Preliminary Results from Study of Adefovir Dipivoxil 10 mg for the Treatment of Patients Co-infected with HIV and Chronic Hepatitis B
Gilead Sciences Announces Third Quarter 2000 Financial Results
Gilead Sciences Presents 48-Week Viral Resistance Data From Phase II Study of Investigational Anti-HIV Agent, Tenofovir DF
New Tamiflu™ Data Shows Early Treatment Optimizes Benefit for Flu Sufferers
Gilead Sciences Announces Results from 48-Week Study of Once-Daily Anti-HIV Agent Tenofovir DF
Gilead Announces Data Demonstrating that Single Dose of AmBisome® Safely and Effectively Treats Visceral Leishmaniasis in India
Pharmacoeconomic Study Compares Total Hospital Costs of AmBisome® to Abelcet® for Empirical Treatment of Patients with Febrile Neutropenia
Roche Submits Tamiflu for Regulatory Approval in Japan; First Oral Neuraminidase Inhibitor for the Treatment and Prevention of Influenza
Second Quarter 2000 Highlights
Gilead Sciences Announces Second Quarter 2000 Financial Results
International AIDS Conference Webcast Attracts Thousands in First Week WEBCAST.AIDS2000.COM
Gilead Sciences Calls for Redemption of Convertible Subordinated Notes
FDA Approves AmBisome® for the Treatment of Cryptococcal Meningitis in AIDS Patients
XIII International Aids Conference to Be Broadcast on World Wide Web WEBCAST.AIDS2000.COM
Roche Seeks to Broaden Tamiflu Treatment Indication with Pediatric Application
Gilead Begins Multinational Phase III Trial of Once-Daily Oral Anti-HIV Drug, Tenofovir Disoproxil Fumarate, in Treatment-Naïve Patients
Roche to Submit Additional Data on Tamiflu for the Treatment of Influenza to the European Regulatory Authorities
Roche Seeks New Tamiflu Indication for the Prevention of Influenza
2000 First Quarter Highlights
Gilead Announces First Quarter 2000 Financial Results
Gilead Sciences Presents 48-Week Phase II Safety and Efficacy Results for Once-Daily Anti-HIV Agent, Tenofovir DF
Gilead Presents Preliminary Clinical Data Describing Activity of Adefovir Dipivoxil Against Lamivudine-Resistant Hepatitis B Virus
Gilead Sciences and EyeTech Pharmaceuticals Announce Exclusive License of Potential New Therapy for Age-Related Macular Degeneration
Canada Approves Antifungal Agent Ambisome®
Gilead and Virco Announce U.S. Collaboration to Promote One of the First Pharmacogenomic Applications for HIV Resistance Tests and Services
Gilead Sciences Announces Changes in Senior Management Team
New AmBisome® Label Includes Claim Of Superior Safety Profile Compared To Abelcet® In Febrile Neutropenic Cancer Patients
Gilead Begins Second Pivotal Phase III Trial of Once Daily Oral Hepatitis B Drug, Adefovir Dipivoxil 10 mg
2012 Interactive Annual Report